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Abstract This article is an historical investigation of the 
term non-steroidal anti-inflammatory drugs and its acronym 
NSAIDs. Drug names and categories tend to be taken at face 
value in everyday practice, as natural categories existing in 
their own right. The main argument of this article is that the 
term NSAID is a reminder that drug names and categories 
are in fact complex cultural and social products that have 
been created by specific people, for specific purposes, 
through specific historical processes, and that this is 
relevant for their use today. The article locates the first 
appearances of the phrase non-steroidal at the entry to the 
1960s, when the iatrogenic tragedies that followed from the 
introduction of corticosteroids had become apparent, and 
where a clear separation between these drugs and emerging 
anti-inflammatory alternatives was needed. The article then 
shows how both the phrase and the acronym appeared for 
the first time out of specific textual contexts in publications 
by Michael W. Whitehouse, before they were taken up by a 
wider community and transformed into concepts 
independent on the context of their first appearances.  
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Origins and impact of the term 'NSAID’.  
In 2012, I did ethnographic fieldwork in a rheumatology 
ward. The purpose was to study processes of interaction of 
health care workers and patients. The term NSAID was in 
frequent use in a way that attracted my interest: It referred 
to a number of drugs, but the name NSAID did not seem to 
add much meaning. Even when written out in full as non-
steroidal anti-inflammatory drugs the term did not say much 
about the drugs it comprised, other than their being anti-
inflammatory, like so many other anti-rheumatic drugs. 
However, in addition, the term NSAID curiously identified 
what the drugs it referred to were not: they were not 
steroids. Why was it necessary, and even pertinent, to 
communicate that Diclofenac, for instance, was not 
Prednisolone? In 2012, Prednisolone and other steroids had 
for several decades been used at low-dose against rheumatic 
diseases (Case, 2001:130), and to me as a newcomer to the 
field, steroids seemed to be a standard, conventional part of 
the rheumatologists’ tool kit. Defining a different group of 
drugs as not steroids did not immediately make sense.  
Looking into the matter, I soon realized that the term 
NSAID, like a lot of other terms in medicine, was not easy 
to examine historically. NSAIDs do “…have anti-
inflammatory, analgesic, and antipyretic properties” 
(Klippel et al., 2010:205); what they don’t have is a 
recorded history. Yet, in the case of NSAIDs, the two first 
letters of the NSAID acronym turned out to function as a 
time capsule, making it possible to set the directions for 
inquiries of the past where the term originated. It turned my 
attention to the introduction to medicine of the thing that 
NSAIDs are not – namely anti-inflammatory steroids. 
The introduction of corticosteroids 
In 1941 Hans Selye had given the first scientific description 
of corticosteroids (Selye, 1941a, Selye 1941b).
1
 Then in 
1949 a corticosteroid treatment was presented for the first 
time in medicine. It was arguably a cure for rheumatic 
arthritis (Case, 2001:130), and the first anti-rheumatic drug 
with disease modifying
2
properties (Whitehouse, 2011:2). As 
                                                          
1 The Editors thank Professor Ludmila Filaretova, St Petersburg for her 
knowledge on the original scientific discovery of corticosteroids. 
2 More than two decades should pass before the term disease-modifying 
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the news leaked from the conference room to the press, 
steroids came to be presented as “a genuine miracle cure”, 
and already the following year the individuals behind its 
discovery received the Nobel Prize (Le Fanu, 2011:33). A 
long feature article in the June 1951 issue of Popular 
Science (Pfeiffer, 1951) provides a salient example of the 
enthusiasm that the discovery of steroids spurred: 
The hormones [ACTH and cortisone] represent 
an entirely new approach in the art of healing. 
Penicillin, streptomycin, the sulfa drugs, and 
most other medicines you’ve been reading about 
are poisons intended specifically to attack 
invading germs. (…) But ACTH and cortisone are 
not germ-killers. They are natural products, 
gland hormones. They influence the body’s built-
in chemical factories that go into action 
whenever extra supplies of tissue are required.  
Using rheumatoid arthritis as example, journalist John E. 
Pfeiffer elaborated on the miraculous effects of steroids: 
The hormone can reshape (…) a deformed joint 
in to  a  smoothly  work ing  fu lcrum.  Pa in 
disappears, and the accumulated debris dissolves. 
Furthermore, destruction of supporting tissue is 
stopped in its tracks for months and fresh cells 
m a y  c o m e  i n  t o  r e p a i r  t h e  d a m a g e . 
While Pfeiffer was aware that there were side-effects to the 
drug, he seemed to interpret those as just other marvels of 
the miracle:  
No modern drugs have so many bizarre and 
baffling effects, wanted and unwanted. How do 
ACTH and cortisone produce excess hair growth 
and a moon-shaped face? Why do they increase 
the multiplication rate of tuberculosis germs - 
and at the same time prevent the disease from 
s p r e a d i n g  i n  t h e  e a r l y  s t a g e s ? 
He perceived the ability to induce euphoria in patients as 
“perhaps the most intriguing effect of all”:  
Cortisone and ACTH are potent ‘pep’ 
preparations. Patients experience a marked 
mental lift after the first doses. They sleep only 
four or five hours a night, and don’t seem to mind 
it. 
In the meantime, physicians and patients learned that the 
side-effects of treatment with these steroids - “…the moon 
face, the perforated and bleeding ulcers, the bruising and 
crushed vertebrae…”(Le Fanu, 2011:34) - were all but 
marvels. The year Pfeiffer published his article in Popular 
Science, the first monograph on steroids’ adverse effects 
(Derbes and Weiss 1951) was also published (Whitehouse 
2011:2). Gradually rheumatologists realized that the 
miracles came at too high a price. Popularity waned and by 
                                                                                   
anti-rheumatic drug (DMARD) was coined. 
the early 1960s, steroid treatment was “shunned altogether 
by the rheumatology community” (Case, 2001:130). An 
anti-steroid zeitgeist arose, and although steroid treatment 
was reborn in the 1980s as a low-dose regimen, its use 
remained controversial (Case, 2001:130). 
Following, on this background it seems reasonable to 
formulate the hypothesis that the concept of NSAIDs had 
been coined not only after the emergence of steroid therapy 
in 1949, but also after the fall from prestige of steroids in 
rheumatology around 1960, and before the revival of 
steroids as a low-dose treatment in the 1980s. PubMed 
searches for the term (on May 5 2014) point to the early 60s 
as the origin of the term “non-steroid”: The earliest mention 
of "non-steroid anti-inflammatory" that I was thus able to 
pinpoint was in the article "A biochemical distinction 
between non-steroid anti-inflammatory and analgesic drugs" 
(Whitehouse, 1963).  
A necessary separation 
I identified the author of this 1963 article as Professor 
Michael W Whitehouse of Griffith University, Brisbane 
Australia.
 3
  As I asked Professor Whitehouse to share any 
information he might have on the forging and popularizing 
of the terms non-steroid anti-inflammatory and NSAIDs, 
Whitehouse described a situation where the steroids and 
their analogues had been overused and mis-prescribed. 
Their euphoric properties had induced addiction in patients, 
and severe side effects had transformed the hopeful 
sufferers into “steroid-wrecks” i.e. “patients with ulcers, 
fragile skin, osteoporosis, impaired immune responses and 
damaging cartilage repair.”  
In the late 1950s and early 1960s, a different family of drugs 
developed from phenylbutazone (indomethacin and 
flufenamic acid among others being introduced in the 
1960s), while pharmaceutical companies were competing to 
introduce ‘super steroids’, failing to disclose the full side-
effects.
4
 The record of iatrogenic tragedies that steroids had 
accumulated, and the problems of deciding whether any 
new drug was or wasn’t related to the known steroids, and 
thus determining the risks related to it, called for moves that 
could clarify the situation. In the early 1960s, no known 
mechanism or other known characteristic could distinguish 
from steroids the drugs that were soon to be known as 
NSAIDs.  
Whitehouse was in the middle of research that provided him 
with the right point of view to produce a conceptual tool 
able to make just such a distinction. Having earned his D 
Phil from the University of Oxford in 1955, he had 
relocated to the Department of Physiological Chemistry at 
the University of Pennsylvania in Philadelphia. There he 
had become acquainted with Howard Holzer and Jay Lash, 
after department chairman Sam Gurin had suggested he go 
and see them in the Anatomy department, one floor below, 
to discuss alternatives to histological staining as ways to 
                                                          
3 Personal communication May 2014. 
4 For details on this, see “Anti-inflammatory glucocorticoid drugs: 
reflections after 60 years” (Whitehouse 2011). 
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characterize embryonic cartilage and distinguish it from 
embryonic muscle: 
‘Borrowing’ their tissue culture system for 
initiating cartilage development from embryonic 
chicken somites, it was easy to confirm that [anti-
inflammatory] steroids poisoned this process.  
From pragmatic solution to independent concept 
Upon his return to Oxford in 1959, Whitehouse analyzed the 
data from the experiments he had conducted in Philadelphia, 
and in 1960 he presented the first results at the first 
International Congress of Endocrinology, Copenhagen. It is 
in the proceedings to that congress, in a short paper entitled 
“Effect of hydrocortisone and some of their synthetic 
analogues upon the biogenesis of cartilage in vitro” 
(Whitehouse and Lash, 1960), that Whitehouse used the 
phrase non-steroid anti-inflammatory for what was probably 
the first time:  
We have studied the effects of a number of 
glucocorticoids and also of some non-steroid 
anti-inflammatory agents upon the biogenesis of 
cartilage in tissue culture. 
The following year, the final version of that paper was 
published as an article in Nature: “Effect of cortisone and 
related compounds on the biogenesis of cartilage” 
(Whitehouse and Lash, 1961). In the article, results with 
different substances were grouped together under three 
separate headings: “Results with Cortisone and 
Hydrocortisone”, “Results with Some Synthetic 
Glucocorticoids”, and “Results with some Non-Steroid 
Anti-inflammatory Agents”. Further the term non-steroid 
appeared twice in the text, in the introduction and in the 
conclusion, in the following sentences: 
For comparison we also observed the effects of 
some non-steroid inflammatory agents upon this 
system in vitro. 
This desirable end is found otherwise with certain 
non-steroid drugs, for example phenylbutazone. 
It is interesting to note that the use of non-steroid in these 
examples can be read as merely resulting from the logic of 
the text. The phrase appears within the pattern ‘X, and non-
X’ (where steroids are X and where “for example 
phenylbutazone”, which is not a steroid, is referred to as 
non-X). This separation categorized, within the context of 
the article, all substances that had been tested. Nothing in 
the text indicates that this was more than a pragmatic 
solution, or that a new concept was about to be introduced 
to medicine. 
But by 1963, however, it is clear that the phrase that 
appeared in the 1960 and 1961 publications had been 
established as an independent concept. In  the article “A 
Biochemical Distinction Between Non-Steroid Anti-
inflammatory and Analgesic Drugs” (Whitehouse, 1963), 
the term non-steroid figures for the first time in a heading, 
but more importantly, the non-X (the non-steroid) appeared 
in a linguistic context where there was no mention of  the X 
(the steroid). Conversely and rather unusually, the 
distinction that was drawn was now between non-X and Y, 
i.e. between “Non-Steroid Anti-Inflammatory Drugs” and 
“Analgesic Drugs.” That the phrase non-steroid anti-
inflammatory drugs had been taken up as a concept by a 
wider research community was evident when in September 
1964 an “International symposium on non-steroidal anti-
inflammatory drugs” was organized in Milan, resulting in 
the publication of a book (Garattini and Dukes, 1965) with 
the term in its title. 
Acronym and concept-acronym 
Still, during the 1960s, the drugs were referred to as non-
steroidal anti-inflammatory drugs, not as NSAIDs, as they 
often are today. Ten years seem to have passed before the 
concept-phrase was challenged in use by its acronym. In 
1973, Paulus and Whitehouse published an article titled 
"Nonsteroid anti-inflammatory agents" (Paulus and 
Whitehouse, 1973), and at the bottom of the first page, the 
authors use the acronym, for the first time, in the following 
sentence: 
Demonstration of the anti-rheumatic properties 
of these new drugs (…) establishes to some 
degree the validity of the rat edema assays for 
selecting moderately effective nonsteroidal "anti-
inflammatory" drugs (NSAIDs). 
The acronym was introduced, it seems, in compliance with 
norms of using acronyms sparingly and fully explained 
when first used. The ambition of the authors, clearly, was 
not to introduce a new term, but to communicate their 
research results to their readers.  
As with the term non-steroid in 1960, it therefore seems as 
though the appearance of the acronym NSAID was 
somehow brought forward by the internal logics of research 
publishing. In a similar way to how the phrase non-steroid 
anti-inflammatory had become concept in its own right, the 
acronym NSAID was soon established as an independent 
concept with no need of explanation. By the late 1970s, the 
acronym even figured in the titles of scientific journal 
articles: “Possible causes of treatment failure with the 
NSAID” (Gylding-Sabroe, 1978), and “Relation between 
ulcerogenic activity of various NSAID and their potency as 
inhibitors of prostaglandin synthesis in vivo” (Strub and 
Muller, 1979), being the two earliest examples of this in 
PubMed.  
Subsequently, the acronym-concept gained popularity and 
widespread use: A PubMed search (on June 3 2014) on the 
term NSAID, resulted in 191.349 hits. A Google search that 
same day resulted in 4.420.000 hits in 0,11 seconds. Today, 
the term NSAID is so widely used that it seems difficult to 
conceptualize any discourse on drug treatments in 
rheumatology without it. In Whitehouse’s own words: 
Though clumsy, the acronym NSAIDs seemed to 
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have served us well; for example, reassuring 
physicians that their use will not produce pseudo-
steroid wrecks, though their patients may still 
suffer stomach (but not skin) ulcers and in 
extreme cases intestinal perforation. 
It is perhaps not insignificant that the popularization of the 
acronym NSAID as an independent concept, which played 
down the message of caution against steroids, coincided 
with a rising awareness of the dangers associated with 
NSAIDs themselves. 
Conclusions 
The term NSAID seems to have been born from a perceived 
need to distinguish new anti-inflammatory drugs from 
steroids, and from the determination of a young researcher, 
Michael Whitehouse, to separate his biochemical studies on 
salicylates and other acidic anti-inflammatories “from the 
odium associated with the anti-inflammatory steroids.” It 
seems that it was the perceived need to separate these drugs 
from the steroids, and the absence of a clear logic for 
internal identification of the emerging group of anti-
inflammatory drugs, was what led Whitehouse to use the 
term “non-steroidal anti-inflammatory”. Doing so, he forged 
a category that reflected his research findings, and which 
defined this emerging field of research at an early point. At 
the same time, the term that he introduced answered to 
needs outside of laboratory research - i.e. in clinical practice 
and public discourse. The concept non-steroid anti-
inflammatory proved useful in the 60s as a tool for handling 
the complexities of inflammopharmacology, by signaling 
what it was not. Later the NSAIDs were to be associated 
with their own series of severe iatrogenic effects, while the 
term as such remained robust. What was introduced as a 
warning has become a thing - and it continues to be useful, 
we must assume, though perhaps for totally different 
reasons. For me, it has been useful as an entry point into the 
rather impenetrable but immensely interesting history of 
development of cultural categories in pharmacology. 
In the excavations I have relayed above, we may well have 
identified the time when the term was coined, the context of 
the coining, and even the originator’s reasons for coining it. 
We may have appreciated some of the uses the term have 
served, and serves today. But we can only speculate on the 
total impact that the rather serendipitous introduction of this 
term has had on rheumatology, on pharmacology in general, 
on drug development, research finance, marketing; on 
clinical communication, patient safety, and so on - over the 
50 years since its coining. A perceived need to minimize 
harm to the patient, deflecting attention away from the 
steroids as prime therapy, seems to have been a driving 
force behind this striking development. On a more detailed 
level, this has required that the term be perceived, again and 
again, as answering to a number of needs of a multitude of 
social actors, actors who have found it opportune to 
perpetuate the use of its term, until the point where its use 
ceased to be a choice, became reflex, and the term was 
established as an entity in its own right.  
The concept seems to have been naturalized in the sense that 
NSAIDs and “non-steroidal anti-inflammatory drugs” 
appear almost as an a priori category, as though the 
category existed before the individual drugs that the 
category comprises appeared, even before the discovery of 
the steroids. This is perhaps the most interesting insight we 
can draw from this investigation. In medical literature and 
everyday language and practices, drug categories such as 
NSAIDs are often taken at face value, as phenomena 
existing in their own right. The term NSAIDs remind us that 
these categories are not a priori given; they have been 
created by specific people, for specific purposes, through 
specific historical processes. They could be different, and 
they needn’t be at all, but being - as complex cultural, 
social, historical creations - and being exactly what they are, 
they have worked not only in our world, but also on it, and 
continue to do so. 
Jonas Kure Buer 
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